Table 1.
Demographics, disease duration, and serologic profile among 2300 SSc patients evaluated from 1990–2009.
| Age of onset < 65 years (n = 2084) | Age of onset > 65 years (n = 216) | p-value | |
|---|---|---|---|
| Female | 1725 (83%) | 184 (85%) | 0.369 |
| African-American | 379 (18%) | 24 (11%) | 0.040 |
| Limited subtype | 1302 (62%) | 147 (68%) | 0.108 |
| Smoking status current or former§ | 992 (48%) | 105 (50%) | 0.601 |
| Median number of visits to Scleroderma Center, range | 3 (1,28) | 2 (1,19) | <0.001 |
| Mean number of years of follow up from first visit to Scleroderma Center among patients with >1 visit§§ (± SD*) | 5 ± 4 | 4 ± 3 | <0.001 |
| Scleroderma Duration, mean ± SD | |||
| Disease duration (years) at time of 1st visit to Scleroderma Center | 6 ± 8 | 2 ± 3 | <0.001 |
| Duration (years) of RP** at time of 1st visit to Scleroderma Center† | 9 ± 10 | 8 ± 13 | 0.4113 |
| Age of first non-RP symptom in years | 43 ± 12 | 71 ± 5 | <0.001 |
| Age of RP onset in years† | 40 ± 13 | 65 ± 13 | <0.001 |
| Years from RP onset to first non-RP SSc symptom† | 3 ± 8 | 6 ± 13 | <0.001 |
| Years from first non-RP SSc symptom to diagnosis of SSc by physician†† | 2 ± 5 | 0.5 ± 2.4 | <0.001 |
| Serology | |||
| ANA | 1259/1306 (96%) | 120/124 (97%) | 0.831 |
| Anti-topoisomerase I | 277/1175 (23%) | 18/107 (17%) | 0.112 |
| Anti-centromere | 348/1288 (27%) | 50/119 (42%) | 0.001 |
| Anti-U1RNP | 102/1084 (9%) | 3/99 (3%) | 0.033 |
§
Data analyzed from 2272 individuals with data recorded regarding smoking status
§§
Data analyzed from 1521 individuals with more than one visit to the Scleroderma Center
*
SD = standard deviation
**
RP = Raynaud phenomenon
†
Data analyzed from 2227 individuals with a reported date of onset for Raynaud phenomenon
††
Data analyzed from 2291 individuals with a reported date of diagnosis by a physician